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Abstract
Tumor size is not a reliable marker for the assessment of early antivascular effects of antiangiogenics. In the present
study, we used 200-μm in-plane high-resolution dynamic contrast-enhanced computed tomography (DCE-CT) to non-
invasively assess the immediate antivascular effects of vandetanib in a subcutaneous human colon cancer (LoVo)
xenograft model in nude rats and to investigate correlation between changes in CT perfusion parameters and tumor
volume or immunohistochemical end points. At 3 to 4 weeks after LoVo cell implantation, the animal was gavaged
with either vandetanib (50 mg/kg) or vehicle twice (22 hours apart) and scanned with a preclinical DCE-CT scanner
before (0 hour) and after treatment (24 hours). Quantitative maps of blood flow (BF) and volume (BV) of the tumor
were calculated from the acquired DCE-CT images. The rats were divided into nonhypovascular, hypovascular, and
combined (regardless of vascularity) groups. In the nonhypovascular group, significant decreases in both tumor BF
and BV were observed in the vandetanib-treated rats compared with increases in the vehicle-treated rats. A signifi-
cant decrease in BV was detected in the vandetanib-treated rats in the combined group as well. No differences in
tumor growth, vascular endothelial growth factor expression, microvessel density, or apoptosis were observed be-
tween vandetanib- and vehicle-treated rats in all three groups. These results demonstrate that BF and BV imaging
biomarkers from DCE-CT imaging can be used for rapid monitoring of immediate (24 hours after) antimicrovascular
effects of vandetanib on tumors, even in the absence of significant changes of tumor volume or clinically relevant
immunohistochemical end points.
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Introduction
A rapid phase of tumor growth occurs when a tumor switches to an
angiogenic phenotype [1,2]. Tumor angiogenesis—the formation of
new blood vessels from existing blood vessels—is initiated by the se-
cretion of various growth factors from tumor cells and the surrounding
stroma [3]. Among the many proangiogenic growth factors, vascular
endothelial growth factor (VEGF) plays a pivotal rate-limiting role in
the angiogenic cascade, enhancing endothelial cell (EC) survival, prolif-
eration, invasion, migration, and capillary tube formation as well as per-
meability of the endothelium [4,5]. Overexpression of VEGF correlates
with increased tumor growth rate, microvessel density (MVD), tumor
metastatic potential, and poor prognosis in a variety of malignancies [6].
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Vandetanib (AstraZeneca, Macclesfield, UK) is an orally bioavailable
inhibitor of VEGF receptor (VEGFR) 2 tyrosine kinase (TK) activity
[7] that has been shown to block tumor-induced angiogenesis through
inhibition of VEGF-induced signaling in ECs in human tumor xeno-
grafts [8–10]. In addition to VEGF signaling inhibition, vandetanib
also inhibits epidermal growth factor receptor TK, although this activity
is not considered essential for antitumor activity in vivo because vande-
tanib has been shown to inhibit tumor growth in a dose-dependent
manner in a histologically diverse panel of human tumor xenografts in-
cluding tumor models that do not respond to gefitinib, a highly selec-
tive epidermal growth factor receptor TK inhibitor [7].
Clinical evaluation of treatment responses relies largely on measure-
ments of tumor size formalized in 1981 as the World Health Organiza-
tion criteria [11] and in 2000 as the Response Evaluation Criteria in
Solid Tumors (RECIST) [12] and this was revised in 2009 [13]. Typi-
cally, serial tumor size assessments are performed several weeks/months
after the drug treatment course/cycle has been started. However, a con-
siderable amount of functional information may be gained by observ-
ing early changes in imaging biomarkers. Furthermore, with the advent
of molecular biology, the focus of drug development has shifted from
cytotoxic chemotherapies to the development of molecular targeted
therapies.Many of these new therapies are expected to be primarily cyto-
static in action, making traditional tumor size response criteria less ap-
propriate for early assessment of drug efficacy. For drugs targeting tumor
vasculature, several tumor biomarkers have been suggested. For exam-
ple, MVD has been shown to correlate with tumor growth, tumor me-
tastasis, and patient prognosis [14–16]. However, because tumor biopsy
is an invasive procedure that is sensitive to sampling variability be-
cause of the underlying heterogeneity of the tumor, it may not be a pre-
ferred option for longitudinal patient monitoring [17]. Thus, there is
a need for the development of noninvasive methods, such as imaging,
that are able to monitor tumor response to antivascular therapies while
potentially providing a better assessment of the response of the whole
tumor [18,19].
Dynamic contrast-enhanced magnetic resonance imaging (DCE-
MRI) has been used extensively in preclinical and clinical settings to
monitor the effect of VEGF signaling inhibitors or vascular disrupting
agents by providing evidence of drug activity on tumor haemodynamics
[20,21], but the practical implementations are not straightforward and
the various analysis strategies used can have considerable consequences
on both the values and the interpretation of the derived parameters [22].
Dynamic contrast-enhanced computed tomography (DCE-CT) has
also been developed recently as a noninvasive in vivo imaging method
to investigate tumor-associated vasculature [23]. The technique bene-
fits from the linear relationship between contrast concentration in both
tissue and blood and image intensity that simplifies modeling to deter-
mine tumor blood flow (BF), blood volume (BV), mean transit time,
and vascular permeability [24,25]. Furthermore, wide availability of
clinical CT scanners, easy implementation of study protocol, and com-
mercially availability of analysis software have resulted in an increasing
use of DCE-CT to study angiogenesis [26,27] in a variety of cancers
and their response to antiangiogenesis therapy and chemo/radiotherapy
in patients [28–30]. Despite this, owing to the limited availability of
preclinical (small animal) CT scanners, DCE-CT has not been used as
extensively as DCE-MRI in testing the effects of antiangiogenics on
tumor vasculature in rodent tumor models.
In the present study, we report the immediate (24 hours) effects of
vandetanib treatment on tumor vasculature measured noninvasively
using quantitative DCE-CT in the LoVo human colon tumor xenograft
model in nude rats with a dedicated high-resolution (200-μm in-plane
resolution) small animal CT scanner.
Materials and Methods
Drugs Preparation
Clinical grade vandetanib was provided by AstraZeneca. Vandetanib
was suspended in 1% (vol./vol.) Tween 80 (Sigma, Oakville, Ontario,
Canada) by gentle milling with equal volume of 6-mm solid glass beads
(Kimble Kontes LLC, Sigma) overnight on blood tube rotator (Ameri-
can Hospital Supply Corp, Miami, FL) at room temperature, and the
suspension was used within 48 hours of preparation. Vandetanib was
administered as a homogeneous suspension by oral gavage at a dosage
of 50 mg/kg body weight.
Cell Culture
The LoVo human colon adenocarcinoma cell line (no. CCL-229;
ATCC, Manassas, VA) was purchased and maintained in F12K growth
medium (Gibco, Burlington, Ontario, Canada), supplemented with
10% fetal bovine serum. Cells were typically passaged twice a week
and were expanded appropriately to yield enough cells to be implanted
into nude rats.
Animals and Tumor Xenograft Model
All experimental procedures were approved by our institutional
research ethics board. Four- to six-week-old male athymic nude rats
(Crl:NIH-rnu) were purchased from Charles River Laboratories
(Wilmington, MA). The rats were caged in groups of two and fed
with standard rodent chow and water ad libitum. On the day of
implant, the LoVo cells were washed with Hank’s balanced salt solu-
tion (Sigma), trypsinized using 0.25% Trypsin-EDTA (Sigma), resus-
pended in growth medium to neutralize the trypsin, and centrifuged
at 600 rpm for 5 minutes to pellet the cells. Cells were then re-
suspended at a concentration of 108 cells/ml in serum-free F12K
medium with penicillin (100 U/ml) and streptomycin (100 μl/ml)
added. One hundred fifty microliters of this cell suspension (1.5 ×
107 cells/rat) was implanted subcutaneously into the left flank of
each nude rat.
Functional DCE-CT Protocol, Schedule of Vandetanib Dosing,
and Blood Collection
Functional DCE-CT imaging was carried out 3 to 4 weeks after
tumor cell transplantation. Inhalation anesthesia in each animal was
induced and maintained with a mixture of oxygen and 0.75% to
1.5% isoflurane administered through a nose cone. A 23-gauge angio-
catheter was placed in a tail vein for subsequent contrast injection.
All imaging was performed with a GE Healthcare eXplore Ultra
small animal CTscanner (London, Ontario, Canada). The CTscanner
is capable of fast rotation speed and collects a complete 360° projection
data set every second for reconstruction into forty-five 0.9-mm-thick
slices covering an axial distance of 4.05 cm. The in-plane resolution
of the CT images is 200 μm (vs ∼750 μm of clinical CT images). An
anteroposterior radiography (scout scan) of the rat was performed to
enable selection of the scan limits for the DCE-CT scanning of the
whole tumor. The DCE-CT scanning consisted of two phases: in the
first phase, the tumor was scanned every second for 30 seconds using
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an x-ray tube voltage of 80 kV(peak) and a tube current of 60 mA and a
1-second gantry rotation time; the second phase was delayed by 10 sec-
onds from the first phase in which the tumor was scanned once every
10 seconds for 150 seconds using the same tube voltage and current.
Nonionic contrast (Omnipaque 300; GE Healthcare, Piscataway, NJ)
at the dosage of 2.2 μl/g (1.7 mmol/kg body weight) was injected using
an infusion pump through the tail vein catheter during 5.0 to 5.8 sec-
onds followed by 0.5 ml of saline injected for 3.8 seconds. The infusion
pump was triggered 5 seconds into the DCE-CT scanning.
After the first DCE-CT scanning, the vandetanib treatment group
(n = 13) was given vandetanib (50 mg/kg) by oral gavage, and the con-
trol group (n = 8) was given the vehicle (1% Tween 80). At 22 hours
after the first dose, rats were given a second dose of vandetanib or vehicle
by oral gavage. At 24 hours after the first dose, all rats were DCE-CT
scanned again.
Before the first dose of vandetanib and immediately after the DCE-
CT scan after the second dose of vandetanib, blood was collected from
the tail vein catheter and plasma was separated for the measurement
of vandetanib concentration. All rats were killed after the second
DCE-CT scan, and blood was collected by intracardiac injection of
potassium chloride. Within 15 to 20 minutes, tumors were excised
and cut into thin (2-3 mm) slices. The slices were fixed in 10% buffered
formalin for 48 hours before being processed for paraffin embedding.
Measurement of Perfusion Parameters: Hypovascular and
Nonhypovascular Groups
The acquired DCE-CT scanning data were reconstructed with a
cone-beam filtered back-projection algorithm into 45 volumes of
forty-six 512 × 512 images each for a total of 2070 images. For each
transverse slice through the tumor, we obtained 45 dynamic images dis-
tributed during the 3-minute scanning time, and the nominal size of
each image voxel was 0.2 × 0.2 × 0.9 mm3. The reconstructed im-
ages were transferred to an Advantage Window workstation (GE
Healthcare) and maps of the absolute value of four perfusion parameters
in the tumor—BF (ml/min per 100 g), BV (ml/100 g),mean transit time
(MTT; second), and permeability surface area product (PS; ml/min per
100 g)—were generated using CT Perfusion 4 (GE Healthcare) devel-
oped in our laboratory [23]. A 2 × 2-pixel region of interest (ROI) was
placed within the aorta to determine the artery concentration versus
time curve, which is needed to calibrate (deconvolve) the tumor contrast
concentration curve for the calculation of perfusion parameters [23].
For each slice, the tumor ROI was defined using an average contrast-
enhanced image, which was generated by averaging all the dynamic
images. The quantitative values of each perfusion parameter in all tumor
ROIs were divided into bins, and the number of pixels in each bin was
expressed as a percentage of the total number of pixels in the whole
tumor to arrive at the normalized histogram of the perfusion parameter.
The mean value of each perfusion parameter in the whole tumor was
obtained as the first moment of the normalized histogram. Tumor vol-
ume (TV) was calculated by multiplying the total number of pixels in
the whole tumor by the pixel volume 0.2mm(x) × 0.2mm ( y) × 0.9mm
(z) = 0.036 mm3. The percentage change in TV after vandetanib or
vehicle treatment was calculated from the following formula: [(1 −
TV after treatment) / TV before treatment] × 100.
The presence or absence of a hypovascular core in every tumor was
examined and confirmed using the CT perfusion maps generated
from the first scan. A hypovascular tumor was defined as follows: at least
one image slice (thickness; 0.9mm) from the whole TV showed a tumor
core with an area greater than 10% of the tumor area and a mean BF less
than 75% of that measured in the left and right erector spinal muscles.
Any rat bearing a hypovascular tumor xenograft as defined above was
assigned to the hypovascular group (n = 12), and those without were
assigned to the nonhypovascular group (n = 9). In the nonhypovascular
group, five were treated with vandetanib and four were treated with
vehicle, whereas in the hypovascular group, eight were treated with van-
detanib and four were treated with vehicle, respectively.
Measurement of Plasma Concentration for Vandetanib
Plasma concentrations of vandetanib was determined by reverse-
phase high-performance liquid chromatography with tandem mass
spectrometry as previously described [31]. The calibration range for
vandetanib was from 5.0 to 1000 ng/ml.
Immunohistochemistry and Image Analysis
The paraffin-embedded tumor samples were cut into 3- to 5-μm-
thick sections. For VEGF staining, two sequential sections were both
placed on the same slide; one section for VEGF staining and another
for negative control staining by omitting the primary antibody. After
overnight incubation at 4°C with the primary antibody that is mouse
monoclonal to VEGF (1:50 dilution; Abcam, Cambridge, MA), sec-
tions were washed and treated with a secondary biotinylated horse anti-
mouse IgG antibody (1:200 dilution; Vectastain avidin-biotin complex
method kit; Vector Laboratories, Burlingame, CA), washed again, ex-
posed to avidin-conjugated horseradish peroxidase H complex, and
incubated in diaminobenzidine and hydrogen peroxide. The slides were
then mounted for image analysis of VEGF expression. For image analy-
sis, each slide with two sequential tumor sections, one of VEGF and
one of negative control staining, was scanned with an Aperio ScanScope
CS scanner (Aperio Technologies, Inc, Vista, CA) at 20×. Using the
Image J program (Image J 1.41o; National Institutes of Health, Be-
thesda, MD; http://rsb.info.nih.gov/ij), the pixel intensity of the Scan-
Scope image was inverted, and a ROI was drawn around the entire
tumor area in the VEGF-stained section for the calculation of the mean
pixel intensity of VEGF expression. To minimize the effect of nonspe-
cific VEGF expression/staining, the mean background pixel intensity in
the negative control section was subtracted from the mean pixel inten-
sity of the VEGF-stained section.
For MVD analysis, the formalin-fixed paraffin-embedded tumors
were sectioned (4 μm), dewaxed, and rehydrated. CD31 staining and
MVD analysis were carried out as previously reported [32]. Antigen
retrieval was done in DAKO buffer S1699 at 121°C for one cycle in a
2100Retriever Pressure Cooker (PickCell Laboratories, Amsterdam, the
Netherlands). All incubations were done at room temperature, and all
washes were done with TBST (100 mM Tris pH 7.4, 150 mM NaCl,
0.05% Tween 20). Endogenous biotin was blocked with avidin-biotin
block (X0590; DAKO, Ely, UK). Sections were blocked with 5% rabbit
serum (DAKO) in TBST for 20 minutes and then incubated in a 1:50
dilution of CD31 antibody (sc-1506) in serum block for 1 hour before
washing. Biotinylated rabbit antigoat immunoglobulin (DAKO), di-
luted 1:200, was then added to the sections for 30 minutes. Vectastain
ABC-Elite solution, diluted as instructed in kit, was then added for
30 minutes, and the sections were developed in diaminobenzidine for
10 minutes (Biogenex, San Ramon, CA) and counterstained weakly
with Carazzi hematoxylin. MVD analysis was done blinded using
an Automated Cellular Imaging System (ACIS; ChromaVisionMedical
Systems, Inc, San Juan Capistrano, CA). Briefly, each tissue section was
scanned into the ACIS at ×10 magnification. Using the ACIS MVD
software algorithm, an analysis threshold was set and applied to all
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tumors within the study. MVD for each tumor was expressed as the
mean number of CD31-positive vascular structures per square milli-
meter of viable tumor.
For apoptosis analysis, cleaved caspase-3 (CC3) rabbit polyclonal
antibodies (Cell Signaling Technology, Danvers, MA) were used fol-
lowed by a one-step horseradish peroxidase–labeled polymer method
(Envision; DAKO). Sections were counterstained with Carazzi hema-
toxylin. CC3-positive staining was expressed as the percent of nuclei
with positive immunostaining.
Statistical Analysis
The nonparametricWilcoxonmatched-pair signed-rank test was used
to compare the changes of CT perfusion parameters (BF, BV, MTT, and
PS) andTV before and after treatment in nonhypovascular and hypovas-
cular tumors as well as the “combined” group (disregarding vascularity).
TheMann-WhitneyU test was used to compare the percentage changes
of CT perfusion parameters and TV, intensity of VEGF expression,
MVD, and percentage CC3 of vehicle- versus vandetanib-treated rats
in all three groups of tumors. Significance was declared at P < .05.
Results
All rats tolerated the anesthesia, DCE-CTscanning, and both vandeta-
nib and vehicle treatments well.
Effects of Vandetanib Treatment on Tumor
Perfusion Parameters
Mean tumor BF, BV, MTT, and PS at baseline (before treatment)
and at 24 hours (2 hours after the second dose of vandetanib or vehicle)
in all groups are shown in Table 1.
Vandetanib reduced tumor BF and BV significantly but not MTT
or PS compared with before treatment (P < .05), whereas vehicle treat-
ment had no significant effects on any of the perfusion parameters. Sub-
group analyses show that the general trend of reduced tumor BF and BV
with vandetanib treatment were maintained in both hypovascular
and nonhypovascular tumors, but only the reduction of BV in non-
hypovascular tumors reached significance. The effects of vandeta-
nib on each perfusion parameter were also investigated as percentage
changes relative to baseline values. In the nonhypovascular group,
marked percentage reductions of both tumor BF (−21.4% ± 25.5%)
and BV (−23.8% ± 20.9%) were observed in vandetanib-treated rats
compared with percentage increases in tumor BF (+18.6% ± 19.3%)
and BV (+50.7% ± 32.3%) in the vehicle-treated rats (both P < .05;
Table 2 and Figure 1), but the percentage changes inMTTand PS were
not significantly different between vandetanib- and vehicle-treated
rats (Table 2 and Figures 1 and 2). In the combined group including
both nonhypovascular and hypovascular tumors, only the percent-
age decrease in BV was significantly different between vandetanib-
and vehicle-treated rats (−15.5% ± 22.9% vs +23.3% ± 36.8%, P <
.01; Table 2 and Figure 3) but not percentage changes in BF, MTT,
or PS (Table 2 and Figure 3). For the hypovascular group, the percent-
age changes in all perfusion parameters (BF, BV, MTT, and PS) did not
differ significantly between vandetanib- and vehicle-treated rats (P > .05;
Table 2 and Figure 4).
Figures 2 and 5 illustrate CT perfusion parametric maps of represen-
tative nonhypovascular and hypovascular tumors, respectively, before
and after vandetanib or vehicle treatment. The nonhypovascular tumors
had relatively uniform BF and BV throughout the tumor. After vehicle
treatment of these tumors, there were notable increases in BF and BV,
particularly in a number of foci, within the tumor region (Figure 2, BF
and BV panels of vehicle control; arrows), suggesting that new micro-
vascular foci with enhanced BF and BV activities had developed during
24 hours in vehicle-treated animals. In contrast, after vandetanib treat-
ment, BF and BV maps in nonhypovascular tumors show notable de-
crease of these parameters (Figure 2, BF and BV panels of vandetanib
treatment). Of interest, there was a suggestion that these effects of van-
detanib treatment were apparent both within the LoVo tumor tissue and
adjacent blood vessels (Figure 2, BF and BV panels of vandetanib treat-
ment ; arrows and dotted arrows), although effects in nontumor tissue
were not quantified in the present study. The hypovascular tumors
had a highly vascular rim, and within, it both BF and BV were much
lower than the rim (Figure 5). Both vandetanib and vehicle treatments
did not affect either tumor BF or BV (Figure 5).
The distributions of BF and BV within a vehicle-treated nonhypo-
vascular tumor are summarized as normalized histograms in Figure 6,
A and C , whereas those for a vandetanib-treated nonhypovascular
tumor are shown as Figure 6, B and D. For the vehicle-treated non-
hypovascular tumor, both tumor BF and BV distributions shifted to
the right (higher values) after vehicle treatment compared with those
before treatment, graphically showing increases in both BF and BV in
the tumor within 24 hours (Figure 6, A and C ). The corresponding
normalized histograms of tumor BF and BV in the vandetanib-treated
nonhypovascular tumor were left-shifted relative to before treatment,
demonstrating that both tumor BF and BV were remarkably inhibited
within 24 hours of treatment with vandetanib (Figure 6, B and D). In
the hypovascular tumor, however, no marked changes in both tumor
BF and BV distributions were found after 24 hours of treatment with
vehicle or vandetanib (Figure 7).
Effects of Vandetanib Treatment on Tumor Growth, VEGF
Expression, MVD, and Apoptosis
We also investigated whether vandetanib treatment was associated
with other tumor responses such as tumor growth inhibition, tumor cell
Table 1. Mean Tumor BF, BV, MTT, and PS Parameters and TV before (at Baseline, 0 hour) and after Treatment (24 hours) in Vandetanib- or Vehicle-Treated Nonhypovascular and Hypovascular
Tumors and All (Combined) Tumors at Week 3 to 4 after Implantation with LoVo Tumor Cells in Nude Rats.
Treatment Group BF (ml/min per 100 g) BV (ml/100 g) MTT (seconds) PS (ml/min per 100 g) TV (mm3)
Before After Before After Before After Before After Before After
Vandetanib Nonhypovascular (n = 5) 86.2 ± 24.9 66.2 ± 24.4 5.4 ± 1.3 4.0* ± 1.1 3.9 ± 8.6 3.8 ± 0.6 22.7 ± 12.0 20.9 ± 11.3 376 ± 126 334 ± 125
Hypovascular (n = 8) 59.9 ± 16.6 53.0 ± 16.0 4.4 ± 1.4 3.8 ± 1.2 4.4 ± 0.5 4.3 ± 0.2 15.1 ± 5.3 14.1 ± 3.0 887 ± 513 855 ± 542
Combined (n = 13) 70.0 ± 23.3 58.1* ± 19.8 4.7 ± 1.4 3.9* ± 1.1 4.2 ± 0.7 4.1 ± 0.5 18.1 ± 8.9 16.7 ± 7.7 691 ± 475 655 ± 497
Vehicle Nonhypovascular (n = 4) 52.1 ± 6.5 61.2 ± 8.0 3.2 ± 0.4 4.7 ± 0.4 3.8 ± 0.8 4.7 ± 0.3 19.2 ± 5.9 16.1 ± 5.0 563 ± 265 550 ± 272
Hypovascular (n = 4) 58.6 ± 18.6 50.0 ± 4.4 4.6 ± 1.3 4.4 ± 1.2 4.7 ± 0.4 5.2 ± 0.9 14.5 ± 4.6 14.8 ± 2.9 744 ± 344 778 ± 483
Combined (n = 8) 55.3 ± 13.4 55.6 ± 8.5 3.9 ± 1.2 4.5 ± 0.8 4.3 ± 0.8 4.9 ± 0.7 16.9 ± 5.5 15.4 ± 3.9 653 ± 300 663 ± 383
Values are mean ± SD.
*Significantly different from before treatment (P < .05) as determined by the Wilcoxon matched-pair signed-rank test.
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death, changes in MVD, or VEGF protein expression during the 24-
hour time frame of the study. As shown in Table 1, before treatment,
the average TVof vandetanib-treated rats was not significantly different
from that of vehicle-treated groups in all three groups (Table 1, TV
in each combined group of vandetanib or vehicle treatment, P > .05). Before
treatment, nonhypovascular tumors were smaller than pretreatment hy-
povascular tumors (average TVs 459 ± 210 mm3 vs 840 ± 452 mm3,
respectively, P < .05; data not shown, but refer to Table 1). In addition,
there was no significant difference in TVs before and after either vehicle
or vandetanib treatment in all three groups.
No significant differences were found in VEGF protein expression
(mean staining intensity), MVD (vessel no./mm2), or tumor apoptosis
(CC3-positive nuclei/total nuclei × 100 [%]) at 24 hours after treat-
ment between vandetanib- and vehicle-treated animals in all three
groups (P ≫ .05; Table 2 and Figures 1, 3, and 4).
Plasma Concentration of Vandetanib
The mean plasma drug concentration in animals sampled 2 hours
after the second of two, 22 hours apart, oral doses of vandetanib
(50 mg/kg each dose) was 1231 ± 337 ng/ml, whereas no vandetanib
was detected in the vehicle-treated controls.
Discussion
The effect of vandetanib has previously been investigated using histol-
ogy, immunohistochemistry, and tumor size measurements in both pre-
clinical and clinical studies [7,8,33]. For in vivo studies, DCE-MRI has
been used in both animals and humans to explore the effects of vande-
tanib on tumor vasculature [34,35]. In the current work, we report on
the use of DCE-CT to evaluate the effects of vandetanib on the vascu-
lature in the LoVo human colon tumor xenograft model in nude rats.
Table 2. Average Percentage Changes (%) in Mean Tumor BF (ml/min per 100 g), BV (ml/100 g), MTT (seconds), PS (ml/min per 100 g), and TV (mm3) Relative to Baseline Values Shown in Table 1
and Average Immunohistochemical End Points for VEGF Expression (Mean Pixel Intensity), MVD (Microvessel Number/mm2), and Apoptosis (CC3-Positive Nuclei/Total Nuclei × 100 [%]) after
Treatment with Vandetanib or Vehicle in Nonhypovascular, Hypovascular, and All (Combined) Tumors at 3 to 4 Weeks After Implantation with LoVo Tumor Cells in Nude Rats.
Group Treatment BF BV MTT PS TV VEGF MVD Apoptosis
Nonhypovascular Vandetanib (n = 5) −21.37* ± 25.5 −23.78* ± 20.9 −0.93 ± 13.2 −3.28 ± 36.6 −10.92 ± 11.7 34.47 ± 10.8 107.40 ± 38.8 3.52 ± 0.8
Vehicle (n = 4) 18.56 ± 19.3 50.67 ± 32.3 28.95 ± 32.5 −10.45 ± 43.5 −3.78 ± 7.6 30.91 ± 3.3 88.58 ± 46.3 3.53 ± 1.2
Hypovascular Vandetanib (n = 8) −10.38 ± 24.1 −10.31 ± 23.9 0.15 ± 10.1 1.82 ± 37.7 −5.49 ± 15.8 29.51 ± 8.3 55.23 ± 16.5 3.59 ± 0.5
Vehicle (n = 4) −10.04 ± 19.8 −4.03 ± 11.2 9.99 ± 23.7 5.30 ± 15.3 3.13 ± 23.8 30.03 ± 8.5 47.96 ± 20.5 2.66 ± 0.7
Combined Vandetanib (n = 13) −14.61 ± 24.3 −15.50† ± 22.9 −0.26 ± 10.8 −0.14 ± 35.8 −7.59 ± 14.1 31.42 ± 9.2 74.20 ± 36.2 3.56 ± 0.6
Vehicle (n = 8) 4.27 ± 23.7 23.30 ± 36.8 19.47 ± 28.2 −2.57 ± 31.3 −0.32 ± 16.8 30.47 ± 6.0 68.27 ± 39.0 3.10 ± 1.0
Values are presented as mean ± SD.
*P ≤ .05, different from the relative change in the vehicle-treated rats as determined by the Mann-Whitney U test.
†P < .01, different from the relative change in the vehicle-treated rats as determined by the Mann-Whitney U test.
Figure 1. Bar graph plots of data from nonhypovascular tumors shown in Table 2. The numbers of animals treated with vehicle (open bar)
and vandetanib (hatched bar) are shown. Values are shown as mean ±SD. *P ≤ .05, different from the vehicle-treated rats as determined
by the Mann-Whitney U test.
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The oral dose of vandetanib in the present study was selected to
achieve plasma drug levels similar to the steady-state plasma levels
achieved in clinical trials with 300 mg of vandetanib daily dosing
[35]. This was confirmed by measurement of the plasma drug level at
2 hours after the second of two, 22 hours apart, oral doses of vandetanib.
Our study with the LoVo xenograft model showed that vandetanib
treatment led to a significant reduction (within 24 hours) of tumor BF
and BV. In contrast, in vehicle-treated animals, both tumor BF and BV
showed a trend of increase during the experiment. When percentage
changes in BF and BV relative to baseline were examined, nonhypo-
vascular tumors showed significant differences between vandetanib
and vehicle treatment, whereas hypovascular tumors did not. Similar
to previous studies, we found that hypovascular tumors are significantly
larger in size than nonhypovascular tumor [36,37]. Furthermore, there
is evidence that maturation of vessels is a function of tumor size [38]. In
view of these prior results, our study suggests that the difference in re-
sponse of nonhypovascular versus hypovascular tumors to vandetanib
may be related to the differential maturation of tumor vessels in the two
types of tumors. It is known thatmature (differentiated) vessels are covered
with pericytes, which make them resistant to VEGF inhibition, whereas
immature (undifferentiated) vessels have less pericyte coverage, and hence,
the ECs are more sensitive to anti-VEGF treatment [38,39]. Thus, the
therapeutic effect of antiangiogenic agents may be dependent on the rel-
ative proportion of mature versus immature vessels in the tumor [40]. Our
study suggests that the vascularity of the tumor may be a surrogate marker
for vessel maturity, but this postulate needs to be further investigated in a
larger study with immunohistopatholgic correlation.
Of interest, our data also suggest that there was a trend for tumor
MTT to decrease or stabilize in vandetanib-treated rats and to increase
in vehicle-treated rats (Table 2 and Figures 1, 3, and 4). MTTmeasures
the time for blood to traverse the microcirculation [23] and therefore
is directly related to interstitial fluid pressure (IFP) in tumors [41]. Tu-
mor vessels are structurally and functionally abnormal: leaky, tortuous,
dilated, saccular, and eccentrically altered [42]. This leakiness of tumor
vessels can lead to extravasation of plasma proteins and fluid, produc-
ing elevated IFP within tumors [42,43], which is a hallmark of solid
tumors. After vandetanib treatment, the stabilized IFP, inferred from
the MTT data, may be a result of vascular normalization acting on
a subset of tumor blood vessels and would be expected to transiently
improve tumor oxygenation thereby potentially limiting the utility of
immunohistochemically associated markers with hypoxia (e.g., VEGF
expression), tumor cell death (e.g., CC3), or tumor cell proliferation
(e.g., Ki67). McCarty et al. [9] reported a striking observation in an
orthotopic model of human gastric cancer in a nude mouse, whereby
after vandetanib treatment for 23 days, remaining tumor vessels had a
three-fold increase in pericyte coverage compared with the control
Figure 2. Representative BF, BV, MTT, and PS maps of a transaxial section through the tumor of one vehicle- and one vandetanib-treated
nonhypovascular tumor before and after treatment. In the BF, BV, MTT, and PS maps, values from 0 to 240 ml/min per 100 g, from 0 to
16 ml/100 g, from 0 to 20 seconds, and from 0 to 100 ml/min per 100 g, respectively, are coded according to the rainbow color scale.
The parametric maps, in particular BF and BV maps, show the level of angiogenic activities in the tumor and adjacent tissue as indicated
by solid and dotted arrows respectively.
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Figure 3. Bar graph plots of data from all tumors (combined) in Table 2. The numbers of animals treated with vehicle (open bar) and vande-
tanib (hatched bar) are shown. Values are shown asmean±SD. *P≤ .01, different from the vehicle-treated rats as determined by theMann-
Whitney U test.
Figure 4. Bar graph plots of data from hypovascular tumors shown in Table 2. The numbers of animals treated with vehicle (open bar) and
vandetanib (hatched bar) are shown. Values are shown as mean ±SD.
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group, supporting the hypothesis of vascular normalization induced by
vandetanib. Additional experiments with longer treatment durations
would be required to evaluate the dynamics of vascular normalization
in the LoVo tumor model used in the present study and could provide
important information for determining the optimal dosing schedule
of vandetanib in combination with standard therapies such as chemo-
therapy and radiotherapy [43].
There were no significant changes in PS after treatment. These results
were similar to those obtained byWillett et al. [44] who showed, also by
using DCE-CT, that a single infusion of the VEGF-specific antibody,
bevacizumab decreased tumor perfusion and vascular volume, but a
change in PS was below the detection limit with DCE-CT in patients
with rectal cancer. This null effect of vandetanib on PS in the present
study is also similar to the results obtained by Raatschen et al. [45]. They
measured PS in MDA MB-435 xenograft tumor using two different
molecular weight x-ray contrast (821 vs 66,000Da). The low–molecular
weight contrast is the same as the one used in this study (Omnipaque;
GE Healthcare). They found that after one dose of bevacizumab, while
PSmeasured with the high–molecular weight contrast decreased signifi-
cantly, that measured with the low–molecular weight contrast did not
change. Although normal endothelium is impermeable to the high–
molecular weight contrast, tumor endothelium is permeable because
of the presence of endothelial fenestrations. With antiangiogenic treat-
ment, the endothelial fenestrations are reduced [46], leading to a de-
crease in PS measured with high–molecular weight agent; however,
although the fenestrations are reduced in size, they are still passable to
low–molecular weight contrast, thus PS measured with low–molecular
weight contrast will not change. As such, it seems that measurement
of PS with high–molecular weight contrast could better reflect the clos-
ing of the fenestrations in tumor endothelium by antiangiogenics than
low–molecular weight contrast [45]. However, as discussed above, the
reduction in the leakage of plasma proteins into the interstitium would
lead to a drop in interstitial pressure and a concomitant decrease in
MTT. Thus, measurement of MTTwith a low–molecular weight as
was the case in the present study could also indicate the closing of endo-
thelial fenestrations in the tumor epithelium. MTT assessment is also
technique-dependent, depending on the temporal resolution, spatial
resolution, and sensitivity.
The complexity and timing of downstream tumor cell responses to
the antivascular effects of VEGF signaling inhibitors, together with
the sampling variability inherent in tumor biopsies suggest that histo-
logic end points may have only limited utility as effective biomarkers
to demonstrate the pharmacodynamic effects of VEGF signaling inhibi-
tors in tumors in the clinic. In rats implanted with FN 13762 tumors
in the liver, Kan et al. [47] used DCE-CT to measure tumor perfu-
sion parameters with and without the VEGFR TK inhibitor SU5416.
In that study, BF, BV, and PS were significantly higher in SU5416-
treated tumors than in control tumors, whereas MVD was significantly
lower. These results for SU5416 differed from the present study with
vandetanib where tumors experienced a significant decrease in both
Figure 5. Representative BF, BV, MTT, and PS maps of a transaxial section through the tumor of one vehicle- and one vandetanib-treated
hypovascular tumorbefore and after treatment. In theBF,BV,MTT, andPSmaps, values from0 to 240ml/minper 100g, from0 to 16ml/100g,
from0 to 20 seconds, and from0 to 100ml/min per 100 g, respectively, are coded according to the rainbowcolor scale. The parametricmaps,
in particular BF and BV maps, show the level of angiogenic activities in the tumors as indicated by the solid arrow.
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BVand BF but no change inMVD or PS. However, compared with the
present study, Kan et al. studied tumors in the orthotopic setting rather
than subcutaneously, and the tumors were much larger with
hypovascular regions. In addition, in that previous study, the DCE-
CTwas performed at baseline and after 2 weeks of treatment, rather than
immediately, as in the present study.
We did not find any significant difference inMVDbetween vandetanib-
and vehicle-treated groups, implying that changes in vascular orga-
nization such as MVD are not expected to occur within 24 hours of
initiating therapy. However, MVD does not discriminate between
functional and nonfunctional tumor blood vessels and may be limited
in revealing the immediate effects of VEGF signaling inhibitors [48].
In addition, we did not observe any difference in tumor cell apoptosis
or VEGF expression. Increased apoptosis has been reported in pre-
clinical tumor models in response to vandetanib [9,49], although these
previous studies evaluated tumor apoptosis after several days or weeks
of treatment and not at very early time points (24 hours) as in the pres-
ent work. VEGF protein expression has been reported to be upregu-
lated in patients treated with VEGF signaling inhibitors, although the
mechanisms underlying this effect are not understood [50]. However,
we did not see any difference in VEGFexpression between vandetanib-
and vehicle-treated tumors in this study whether they were hypo-
vascular or not. This could be due to the short duration of treatment
(24 hours) used in the present study, high constitutive expression of
VEGF through non–hypoxia-regulated pathways [51] and/or vessel
normalization transiently improving oxygen delivery despite the over-
all reduction in tumor BF and BV [42].
Compared with other imaging modalities that can be used to mea-
sure tumor perfusion, CT has a number of advantages [23,25]. Firstly,
it rivals the ability of PET for kinetic modeling of the uptake of contrast
because tissue contrast concentration can be accurately and quantita-
tively measured. Secondly, it has the highest combination of temporal
frequency (∼1 Hz) and spatial resolution in dynamic scanning, which
permits the accurate characterization of the uptake and washout of
contrast agent with submillimeter resolution, in this case 0.18 mm.
Thirdly, the arterial input curve can be measured from the same dy-
namic CT images as the tissue concentration [23], obviating the need
for invasive arterial sampling or more complicated postprocessing of
image data [52,53]. Fourthly, CT is widely accessible in most hospitals
and is not limited to academic or tertiary hospitals. DCE-MRI also
offers many of the advantages of DCE-CTwithout the inconvenience
of ionizing radiation or limited coverage. However, the technique is
hampered by its complexity and the lack of straightforward relationship
between signal intensity and contrast agent concentration, which make
the results more difficult to interpret [22,24]. Also, DCE-MRImay not
be feasible for some patient groups, especially individuals with kidney
failure (because of the risk of nephrogenic systemic fibrosis), those with
implanted devices (cardiac pacemakers, prosthetic valves, intracranial an-
eurismal clips, shrapnel injury), and thosewith severe claustrophobia [22].
One limitation of DCE-CTas developed in this study for the moni-
toring of therapy is the relatively high radiation dose, which can be as
high as 20 mSv [54]. Although radiation dose is limited in a single
DCE-CT study, the accumulated radiation dose from multiple DCE-
CT studies to monitor the effect of therapy over time may pose a
Figure 6. The corresponding normalized whole tumor BF and BV histograms of the nonhypovascular tumors shown in Figure 2 before and
after treatment with vehicle (A, C) and vandetanib (B, D).
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concern. However, advances in CT reconstruction techniques, such as
the statistical iterative method proposed by Thibault et al. [55], may
significantly reduce the radiation dose without sacrificing image quality.
The application of these image reconstruction algorithms toDCE-CT is
currently under investigation. Another limitation is the contrast-
induced nephrotoxicity such that patients with poor renal function
(i.e., estimated glomerular filtration rate <30ml/min) have to be excluded.
In conclusion, our study demonstrated that DCE-CT can detect the
immediate effects of vandetanib, given twice orally during 24 hours, on
tumor vasculature in the absence of significant effects on TV or histo-
logic markers. As such, DCE-CT has promise for early, noninvasive
assessment of vascular response to antiangiogenesis agents in the clinic,
in particular, allowing broader clinical utility than more complex func-
tional imaging modalities such as DCE-MRI.
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